Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.50 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15762727 | 0.86 | ALDH1A1 (0.48) | KDM4EKMT2APOLBROCK2LMNA | |
| SCHEMBL27349602 | 0.85 | CYP19A1 (0.47) | CYP19A1CYP17A1KDM4EKMT2APOLB | |
| SCHEMBL10033500 | 0.84 | CYP19A1 (0.46) | CYP19A1CYP17A1KDM4EKMT2APOLB | |
| SCHEMBL19582142 | 0.82 | CYP19A1 (0.45) | CYP19A1CYP17A1KDM4EKMT2APOLB | |
| SCHEMBL19582143 | 0.82 | CYP19A1 (0.45) | CYP19A1CYP17A1KDM4EKMT2APOLB | |
| SCHEMBL2945515 | 0.80 | ALDH1A1 (0.64) | CYP19A1CYP17A1KDM4EKMT2APOLB | |
| SCHEMBL112859 | 0.80 | ALDH1A1 (0.64) | KMT2AMAPTLMNAMAPK1ALDH1A1 | |
| SCHEMBL4244228 | 0.79 | KMT2A (0.53) | CYP19A1CYP17A1KDM4EKMT2APOLB | |
| SCHEMBL22310962 | 0.79 | CA1 (0.60) | CYP19A1CYP17A1KDM4EKMT2APOLB | |
| SCHEMBL22752185 | 0.79 | KMT2A (0.53) | CYP19A1CYP17A1KDM4EKMT2ANAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230015308-A1 | SUBSTITUTED THIAZOLE AROMATIC RING-BASED COMPOUND AND PREPARATION METHOD THEREFOR, HERBICIDAL COMPOSITION AND USE THEREOF | QINGDAO KINGAGROOT CHEMICAL COMPOUND CO., LTD. (CN) | 2023-01-19 | — | — | US | disclosed |
| US-20180009805-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-11 | — | — | US | disclosed |
| US-8278099-B1 | Monoclonal antibody to human thrombopoietin | GENENTECH, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8241900-B1 | mpl ligand | GENENTECH, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8192955-B1 | Nucleic acids encoding MPL ligand (thrombopoietin), variants, and fragments thereof | GENENTECH, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8192955-B1 | Nucleic acids encoding MPL ligand (thrombopoietin), variants, and fragments thereof | GENENTECH, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193323-B1 | mpl ligand (thrombopoietin), active fragments thereof, and fusion proteins and compositions comprising mpl ligand and other cytokines | GENENTECH, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8178107-B1 | Method of treatment of thrombocytopenia or risk thereof using MPL ligand (thrombopoietin), variants, and fragments thereof | GENENTECH, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8147844-B1 | Mpl ligand (thrombopoietin), nucleic acids encoding such, and methods of treatment using mpl ligand | GENENTECH, INC. (US) | 2012-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230015308-A1 | SUBSTITUTED THIAZOLE AROMATIC RING-BASED COMPOUND AND PREPARATION METHOD THEREFOR, HERBICIDAL COMPOSITION AND USE THEREOF | WEE1, CBR3, GLRX3 | CYP19A1 848/4885CYP17A1 656/4885KDM4E 2091/4885 |
| US-20180009805-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | TAF1, TAF1L, TAF1B | CYP19A1 2810/4885CYP17A1 1855/4885KDM4E 2669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.